Profil

HAAN Claude

University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM)

Main Referenced Co-authors
BEHRMANN, Iris  (32)
HAAN, Serge  (15)
Heinrich, P. C. (11)
ROLVERING, Catherine  (11)
KREIS, Stephanie  (10)
Main Referenced Keywords
Humans (13); Animals (12); Janus Kinase 1 (11); Signal Transduction (9); Protein-Tyrosine Kinases (8);
Main Referenced Unit & Research Centers
University of Luxembourg (4)
Luxembourg Centre for Systems Biomedicine (LCSB): Metabolomics (Hiller Group) (1)
ULHPC - University of Luxembourg: High Performance Computing (1)
Main Referenced Disciplines
Biochemistry, biophysics & molecular biology (41)
Microbiology (1)
Life sciences: Multidisciplinary, general & others (1)

Publications (total 43)

The most downloaded
1359 downloads
Haan, C., & Behrmann, I. (2007). A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. Journal of Immunological Methods, 318 (1-2), 11-9. doi:10.1016/j.jim.2006.07.027 https://hdl.handle.net/10993/6227

The most cited

197 citations (Scopus®)

Haan, C., & Behrmann, I. (2007). A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. Journal of Immunological Methods, 318 (1-2), 11-9. doi:10.1016/j.jim.2006.07.027 https://hdl.handle.net/10993/6227

Reigstad, A., Herdlevær, C. F., Rigg, E., Hoang, T., Bjørnstad, O. V., Aasen, S. N., Preis, J. R., Haan, C., Sundstrøm, T., & Thorsen, F. (2022). CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells. PLoS ONE. doi:10.1371/journal.pone.0273711
Peer Reviewed verified by ORBi

Kirchmeyer, M., Servais, F., Ginolhac, A., Nazarov, P. V., Margue, C., Philippidou, D., Nicot, N., Behrmann, I., Haan, C., & Kreis, S. (2020). Systematic transcriptional profiling of responses to STAT1- and STAT3- activating cytokines in different cancer types. Journal of Molecular Biology. doi:10.1016/j.jmb.2020.09.011
Peer Reviewed verified by ORBi

Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (15 February 2019). Many ways to resistance: How melanoma cells evade targeted therapies. Biochimica et Biophysica Acta - Reviews on Cancer, 1871 (2), 313-322. doi:10.1016/j.bbcan.2019.02.002
Peer Reviewed verified by ORBi

Margue, C., Philippidou, D., Kozar, I., Cesi, G., Felten, P., Kulms, D., Letellier, E., Haan, C., & Kreis, S. (February 2019). Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. Journal of Experimental and Clinical Cancer Research, 38 (1). doi:10.1186/s13046-019-1038-x
Peer Reviewed verified by ORBi

Servais, F., Kirchmeyer, M., Hamdorf, M., Minoungou, W. N., Rose-John, S., Kreis, S., Haan, C., & Behrmann, I. (2019). Modulation of the IL-6 signaling pathway in liver cells by miRNAs targeting gp130, JAK1 and/or STAT3. Molecular Therapy: Nucleic Acids, 16, 419-433. doi:10.1016/j.omtn.2019.03.007
Peer Reviewed verified by ORBi

Cesi, G., Philippidou, D., Kozar, I., Kim, Y. J., Bernardin, F., Van Niel, G., Wienecke-Baldacchino, A., Felten, P., Letellier, E., Dengler, S., Nashan, D., Haan, C., & Kreis, S. (2018). A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. Molecular Cancer, (17:145). doi:10.1186/s12943-018-0886-x
Peer Reviewed verified by ORBi

Rolvering, C., Zimmer, A. D., Ginolhac, A., Margue, C., Kirchmeyer, M., Servais, F., Hermanns, H. M., Hergovits, S., Nazarov, P. V., Nicot, N., Kreis, S., Haan, S., Behrmann, I., & Haan, C. (2018). The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by a-PD-L1 or a-IL6 antibodies. Journal of Leukocyte Biology, 104, 969-985. doi:10.1002/JLB.MA1217-495R
Peer Reviewed verified by ORBi

Cesi, G., Walbrecq, G., Zimmer, A. D., Kreis, S., & Haan, C. (08 June 2017). ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Molecular Cancer, 8 (june). doi:10.1186/s12943-017-0667-y
Peer Reviewed verified by ORBi

Rolvering, C., Zimmer, A., Kozar, I., Hermanns, Letellier, E., Vallar, L., Nazarov, P., Nicot, N., Ginolhac, A., Haan, S., Behrmann, I., & Haan, C. (2017). Crosstalk between different family members: IL27 recapitulates IFNγ responses in HCC cells, but is inhibited by IL6-type cytokines. BBA Molecular Cell Research, 516-526. doi:10.1016/J.BBAMCR.2016.12.006
Peer Reviewed verified by ORBi

Bongartz, H., Hessenkemper, W., Müller, C., Fensky, M., Fritsch, J., Mandel, K., Behrmann, I., Haan, C., Fischer, T., Feller, S. M., & Schaper, F. (2017). The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617Fpositive cells and mediates proliferation of human erythroleukaemia cells. Cellular Signalling, 35, 37-47. doi:10.1016/j.cellsig.2017.03.021
Peer reviewed

Zimmer, A. D., Walbrecq, G., Kozar, I., Behrmann, I., & Haan, C. (2016). Phosphorylation of the PDH complex precedes HIF-1-mediated effects and PDK1 upregulation during the first hours of hypoxic treatment in HCC cells. Hypoxia, 4, 135-145. doi:10.2147/HP.S99044
Peer reviewed

Battello, N., Zimmer, A. D., Goebel, C., Dong, X., Behrmann, I., Haan, C., Hiller, K., & Wegner, A. (2016). The role of HIF-1 in oncostatin M-dependent metabolic reprogramming of hepatic cells. Cancer and Metabolism, 4, 3. doi:10.1186/s40170-016-0141-0
Peer Reviewed verified by ORBi

Haan, S., Bahlawane, C., Wang, J., Nazarov, P. V., Muller, A., Eulenfeld, R., Haan, C., Rolvering, C., Vallar, L., Satagopam, V., Sauter, T., & Wiesinger, M. (2015). The oncogenic FIP1L1-PDGFRalpha fusion protein displays skewed signaling properties compared to its wild-type PDGFRalpha counterpart. JAK-STAT, 4 (1), 1062596. doi:10.1080/21623996.2015.1062596
Peer reviewed

Servais, F., Kirchmeyer, M., Hamdorf, M., Haan, C., Casper, M., Lammert, F., Nazarov, P., Vallar, L., Kreis, S., & Behrmann, I. (2015). ID: 194: Role of microRNAs in signal transduction pathways of the inflammatory cytokine Interleukin-6: Relevance for liver diseases. Cytokine, 76 (1), 99. doi:10.1016/j.cyto.2015.08.198
Peer reviewed

Gäbler, K., Behrmann, I., & Haan, C. (2013). JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAK-STAT, 2 (3), 25025. doi:10.4161/jkst25025
Peer reviewed

Wolf, A., Eulenfeld, R., Gäbler, K., Rolvering, C., Haan, S., Behrmann, I., Denecke, B., Haan, C., & Schaper, F. (2013). JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells. JAK-STAT, 2 (3), 24574. doi:10.4161/jkst.24574
Peer reviewed

Gäbler, K., Rolvering, C., Kaczor, J., Eulenfeld, R., Méndez, S. A., Berchem, G., Palissot, V., Behrmann, I., & Haan, C. (2013). Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. Journal of Cellular and Molecular Medicine, 17 (2), 265-276. doi:10.1111/jcmm.12005
Peer reviewed

Haan, C., & Haan, S. (2013). Co-immunoprecipitation protocol to investigate cytokine receptor-associated proteins, e.g., Janus kinases or other associated signaling proteins. Methods in Molecular Biology, 967, 21-38. doi:10.1007/978-1-62703-242-1_2
Peer reviewed

Haan, S., & Haan, C. (2013). Detection of activated STAT species using electrophoretic mobility shift assay (EMSA) and potential pitfalls arising from the use of detergents. Methods in Molecular Biology, 967, 147-59. doi:10.1007/978-1-62703-242-1_10
Peer reviewed

Haan, C., Ungureanu, D., Pekkala, T., Silvennoinen, O., & Haan, S. (2012). Regulation of JAKs: Insights gleaned from the functional protein domains. In T. Decker & M. Müller (Eds.), JAK-STAT Signaling – From Basics to Disease (pp. 5-25). Wien, Austria: Springer-Verlag. doi:10.1007/978-3-7091-0891-8_2

Haan, C., Rolvering, C., Raulf, F., Kapp, M., Drückes, P., Thoma, G., Behrmann, I., & Zerwes, H.-G. (2011). Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chemistry and Biology, 18 (3), 314-323. doi:10.1016/j.chembiol.2011.01.012
Peer reviewed

Vollmer, S., Haan, C., & Behrmann, I. (2010). Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells. Biochemical Pharmacology, 80 (12), 2066-2073. doi:10.1016/j.bcp.2010.07.015
Peer reviewed

Haan, C., Behrmann, I., & Haan, S. (2010). Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. Journal of Cellular and Molecular Medicine, 14 (3), 504-27. doi:10.1111/j.1582-4934.2010.01018.x
Peer reviewed

Haan, C., Kroy, D. C., Wüller, S., Sommer, U., Nöcker, T., Rolvering, C., Behrmann, I., Heinrich, P. C., & Haan, S. (2009). An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. Journal of Immunology, 182 (5), 2969-2977. doi:10.4049/jimmunol.0800572
Peer Reviewed verified by ORBi

Haan, S., Wuller, S., Kaczor, J., Rolvering, C., Nocker, T., Behrmann, I., & Haan, C. (2009). SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene, 28 (34), 3069-80. doi:10.1038/onc.2009.155
Peer Reviewed verified by ORBi

Hintzen, C., Haan, C., Tuckermann, J. P., Heinrich, P. C., & Hermanns, H. M. (2009). Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. Journal of Immunology, 181 (10), 7341-7349. doi:10.4049/jimmunol.181.10.7341
Peer Reviewed verified by ORBi

Bender, H., Wiesinger, M., Nordhoff, C., Schoenherr, C., Haan, C., Ludwig, S., Weiskirchen, R., Kato, N., Heinrich, P. C., & Haan, S. (2009). Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes. Hepatology, 50 (2), 585-91. doi:10.1002/hep.22988
Peer Reviewed verified by ORBi

Vollmer, S., Kappler, V., Kaczor, J., Flügel, D., Rolvering, C., Kato, N., Kietzmann, T., Behrmann, I., & Haan, C. (2009). Hypoxia-inducible factor 1alpha is up-regulated by oncostatin M and participates in oncostatin M signaling. Hepatology, 2009 (3). doi:10.1002/hep.22928
Peer Reviewed verified by ORBi

Haan, S., Margue, C., Engrand, A., Rolvering, C., Schmitz-Van de Leur, H., Heinrich, P. C., Behrmann, I., & Haan, C. (2008). Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. Journal of Immunology, 180 (2), 998-1007. doi:10.4049/jimmunol.180.2.998
Peer Reviewed verified by ORBi

Haan, C., & Behrmann, I. (2007). A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. Journal of Immunological Methods, 318 (1-2), 11-9. doi:10.1016/j.jim.2006.07.027
Peer reviewed

Kreis, S., Philippidou, D., Margue, C., Rolvering, C., Haan, C., Dumoutier, L., Renauld, J.-C., & Behrmann, I. (2007). Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS ONE, 2 (12), 1300. doi:10.1371/journal.pone.0001300
Peer Reviewed verified by ORBi

Haan, C., Kreis, S., Margue, C., & Behrmann, I. (November 2006). Jaks and cytokine receptors - an intimate relationship. Biochemical Pharmacology, 72 (11), 1538-46. doi:10.1016/j.bcp.2006.04.013
Peer reviewed

Haan, S., Keller, J. F., Behrmann, I., Heinrich, P. C., & Haan, C. (2005). Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cellular Signalling, 17 (12), 1542-50. doi:10.1016/j.cellsig.2005.03.010
Peer Reviewed verified by ORBi

Radtke, S.* , Haan, S.* , Jörissen, A.* , Hermanns, H. M., Diefenbach, S., Smyczek, T., Schmitz-Vandeleur, H., Heinrich, P. C., Behrmann, I., & Haan, C. (2005). The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. Journal of Biological Chemistry, 280 (27), 25760-8. doi:10.1074/jbc.M500822200
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Behrmann, I., Smyczek, T., Heinrich, P. C., Schmitz-Van de Leur, H., Komyod, W., Giese, B., Muller-Newen, G., Haan, S., & Haan, C. (2004). Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase. Journal of Biological Chemistry, 279 (34), 35486-93. doi:10.1074/jbc.M404202200
Peer Reviewed verified by ORBi

Giese, B., Au-Yeung, C. K., Herrmann, A., Diefenbach, S., Haan, C., Küster, A., Wortmann, S. B., Roderburg, C., Heinrich, P. C., Behrmann, I., & Müller-Newen, G. (2003). Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. Journal of Biological Chemistry, 278 (40), 39205-13. doi:10.1074/jbc.M303347200
Peer Reviewed verified by ORBi

Radtke, S., Hermanns, H. M., Haan, C., Schmitz-Van De Leur, H., Gascan, H., Heinrich, P. C., & Behrmann, I. (2002). Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. Journal of Biological Chemistry, 277 (13), 11297-305. doi:10.1074/jbc.M100822200
Peer Reviewed verified by ORBi

Haan, C., Heinrich, P. C., & Behrmann, I. (2001). Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. Biochemical Journal, 361 (Pt 1), 105-11. doi:10.1042/0264-6021:3610105
Peer Reviewed verified by ORBi

Haan, C., Isharc, H., Hermanns, H. M., Schmitz-Van De Leur, H., Kerr, I. M., Heinrich, P. C., Grötzinger, J., & Behrmann, I. (2001). Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. Journal of Biological Chemistry, 276 (40), 37451-8. doi:10.1074/jbc.M106135200
Peer Reviewed verified by ORBi

Haan, C., Hermanns, H. M., Heinrich, P. C., & Behrmann, I. (2001). A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction. Biochemical Journal, 349 (Pt 1), 261-6. doi:10.1042/0264-6021:3490261
Peer Reviewed verified by ORBi

Hermanns, H. M., Radtke, S., Haan, C., Schmitz-Van de Leur, H., Tavernier, J., Heinrich, P. C., & Behrmann, I. (2000). Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. Journal of Immunology, 163 (12), 6651-8.
Peer Reviewed verified by ORBi

Thiel, S., Sommer, U., Kortylewski, M., Haan, C., Behrmann, I., Heinrich, P. C., & Graeve, L. (2000). Termination of IL-6-induced STAT activation is independent of receptor internalization but requires de novo protein synthesis. FEBS Letters, 470 (1), 15-9. doi:10.1016/S0014-5793(00)01276-X
Peer Reviewed verified by ORBi

Behrmann, I., Hermanns, H. M., Haan, C., Kortylewski, M., Radtke, S., Greiser, J. S., & Heinrich, P. C. (2000). Signalling of interleukin-6 type cytokines via gp130, leukemia inhibitory factor (LIF) receptor and oncostatin M receptor. European Cytokine Network, 11 (3), 491-2.
Peer Reviewed verified by ORBi

Contact ORBilu